A Phase I Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-2575 in Patients with Hematologic Malignancies
MD Anderson Study Status
This is a multi-center, single-agent, open-label, Phase I study of APG-2575. The study consists of the dose escalation stage and the dose expansion stage.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
For general questions about clinical trials: